Research map: T-type calcium channel blockers: a review of recent advances (2018–2025)

Back to the article

Papers in this map

  1. Molecular Physiology of Low-Voltage-Activated T-type Calcium Channels · Edward Perez‐Reyes · 2003 · 1671 citations · Cited by this paper
  2. Sirtuin modulators: a review of patents from 2020 to 2024 · 2025 · Related
  3. The Physiology, Pathology, and Pharmacology of Voltage-Gated Calcium Channels and Their Future Therapeutic Potential · Gerald Werner Zamponi · 2015 · 1140 citations · Cited by this paper
  4. A patent review of Mpro protease inhibitors for the treatment of COVID-19 infections (2020 – present) · 2025 · Related
  5. The anti-angiogenic agent fumagillin covalently binds and inhibits the methionine aminopeptidase, MetAP-2 · Ny Sin · 1997 · 637 citations · Cited by this paper
  6. Therapeutic applications of benzoxaborole compounds: a patent and literature analysis (2019–2024) · 2025 · Related
  7. Pharmacological significance of triazole scaffold · Rajeev Kharb · 2010 · 598 citations · Cited by this paper
  8. An updated patent review of histone deacetylase 6 inhibitors in neurodegenerative diseases (2020–2025) · 2026 · Related
  9. A novel T-type current underlies prolonged Ca(2+)-dependent burst firing in GABAergic neurons of rat thalamic reticular nucleus · JR Huguenard · 1992 · 571 citations · Cited by this paper
  10. 5’-Ectonucleotidase (CD73) inhibitors: a patent review (2021-present) · 2026 · Related
  11. Silencing of the Cav3.2 T‐type calcium channel gene in sensory neurons demonstrates its major role in nociception · Emmanuel Bourinet · 2004 · 456 citations · Cited by this paper
  12. PCSK9 inhibitors: an updated patent review 2024–2025 · 2026 · Related
  13. The need for new approaches in CNS drug discovery: Why drugs have failed, and what can be done to improve outcomes · Valentin K. Gribkoff · 2016 · 381 citations · Cited by this paper
  14. Topoisomerase II inhibitors in oncology: an updated patent review (2016-present) · 2025 · Related
  15. Targeting voltage-gated calcium channels in neurological and psychiatric diseases · Gerald Werner Zamponi · 2015 · 378 citations · Cited by this paper
  16. Recent advances in the discovery of PKMYT1-targeting drugs: a patent review (2021–2025) · 2026 · Related
  17. Calcium-Permeable Ion Channels in Pain Signaling · Emmanuel Bourinet · 2014 · 339 citations · Cited by this paper
  18. Implementation and outcomes of China’s drug patent linkage system: lessons from international experience · 2025 · Related
  19. Biological potential of carbazole derivatives · Agata Głuszyńska · 2015 · 283 citations · Cited by this paper
  20. An updated patent review of acetylcholinesterase inhibitors for the treatment of Alzheimer’s disease (2021–present) · 2025 · Related
  21. The Deubiquitinating Enzyme USP5 Modulates Neuropathic and Inflammatory Pain by Enhancing Cav3.2 Channel Activity · Agustı́n Garcı́a-Caballero · 2014 · 259 citations · Cited by this paper
  22. Dual- and Triple-Acting Agents for Treating Core and Co-morbid Symptoms of Major Depression: Novel Concepts, New Drugs · Mark John Millan · 2008 · 197 citations · Cited by this paper
  23. Levetiracetam: a review of its use in epilepsy. · Katherine Ann Lyseng-Williamson · 2011 · 196 citations · Cited by this paper
  24. Cryo-EM structures of apo and antagonist-bound human Cav3.1 · Yanyu Zhao · 2019 · 196 citations · Cited by this paper
  25. Differential Inhibition of T-Type Calcium Channels by Neuroleptics · Celia Maria Santi · 2002 · 191 citations · Cited by this paper
  26. Gating Effects of Mutations in the Cav3.2 T-type Calcium Channel Associated with Childhood Absence Epilepsy · Houman Khosravani · 2004 · 185 citations · Cited by this paper
  27. TTA-P2 Is a Potent and Selective Blocker of T-Type Calcium Channels in Rat Sensory Neurons and a Novel Antinociceptive Agent · Won Joo Choe · 2011 · 179 citations · Cited by this paper
  28. Thiazolidine-2,4-diones: Progress towards multifarious applications · Viral S. Jain · 2013 · 165 citations · Cited by this paper
  29. Design, Synthesis, and Evaluation of a Novel 4-Aminomethyl-4-fluoropiperidine as a T-Type Ca2+Channel Antagonist · William D. Shipe · 2008 · 140 citations · Cited by this paper
  30. Ethosuximide: From Bench to Bedside · Mehmet Zafer Gören · 2007 · 132 citations · Cited by this paper
  31. Recent advances in the development of T‐type calcium channel blockers for pain intervention · Terrance P. Snutch · 2017 · 126 citations · Cited by this paper
  32. State-dependent properties of a new T-type calcium channel blocker enhance CaV3.2 selectivity and support analgesic effects · Amaury François · 2012 · 118 citations · Cited by this paper
  33. The I–II Loop Controls Plasma Membrane Expression and Gating of Cav3.2 T-Type Ca2+Channels: A Paradigm for Childhood Absence Epilepsy Mutations · Iuliia Vitko · 2007 · 115 citations · Cited by this paper
  34. De novo mutation screening in childhood-onset cerebellar atrophy identifies gain-of-function mutations in the CACNA1G calcium channel gene · Jean Chemin · 2018 · 113 citations · Cited by this paper
  35. Small Organic Molecule Disruptors of Cav3.2 - USP5 Interactions Reverse Inflammatory and Neuropathic Pain · Vinícius M. Gadotti · 2015 · 105 citations · Cited by this paper
  36. Genetic T-type calcium channelopathies · Norbert Weiss · 2019 · 95 citations · Cited by this paper
  37. What lessons can be learnt from withdrawal of mibefradil from the market? · A. Li Wan Po · 1998 · 94 citations · Cited by this paper
  38. PROTAC degraders as chemical probes for studying target biology and target validation · Václav Němec · 2022 · 93 citations · Cited by this paper
  39. Drug-drug interactions of new active substances: mibefradil example · Krayenbühl Jc · 1999 · 90 citations · Cited by this paper

Source: OpenAlex (CC0)